Im­muno­vant’s $450M pri­vate place­ment; Bio­mea be­comes an obe­si­ty biotech

Plus, news about Ash­vattha, Bausch + Lomb, White­cap Bio­sciences, Lab­vi­va, Scribe, Sanofi, X4, Apel­lis and Aileron Ther­a­peu­tics:

Im­muno­vant nets $450M pri­vate place­ment: The pro­ceeds will help …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER